ORAL MEDICATIONS FOR MS! Gilenya and Aubagio



Similar documents
Aubagio. Aubagio (teriflunomide) Description

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY

RISK EVALUATION AND MITIGATION STRATEGY (REMS)

Progress in MS: Current and Emerging Therapies

Teriflunomide is the active metabolite of Leflunomide, a drug employed since 1994 for the treatment of rheumatoid arthritis (Baselt, 2011).

Disease Modifying Therapies for MS

Medication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010

Which injectable medication should I take for relapsing-remitting multiple sclerosis?

MS Treatments Aubagio TM

New treatments in MS What s here and what s nearly here

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Committee Approval Date: December 12, 2014 Next Review Date: December 2015

Version History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author

New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents

Brand Name: Gilenya. Generic Name: Fingolimod. Manufacturer 1 : Novartis Pharmaceutical Corporation

A neurologist would assess your eligibility and suitability for the DMTs.

Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI)

Disease Modifying Therapies for MS

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

National Multiple Sclerosis Society. Disease Modification in Multiple Sclerosis. Current as of January 2, 2013

Gilenya. Exceptional healthcare, personally delivered

AUBAGIO Conversation Starter

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

The MS Disease- Modifying Medications GENERAL INFORMATION

MS Treatments Gilenya

this 7^ day of September 2014 by Randall S. Gregg Special Deputy Director

New Treatment Options for MS Patients: Understanding risks versus benefits

National MS Society Information Sourcebook

Genzyme s Multiple Sclerosis Franchise Featured at AAN

J.P. Morgan Cazenove Therapeutic Seminar

teriflunomide, 14mg, film-coated tablets (Aubagio ) SMC No. (940/14) Genzyme Ltd.

Original Policy Date

Treatments for MS: Immunotherapy. Gilenya (fingolimod) Glatiramer acetate (Copaxone )

Disease modifying drug therapy

Information About Medicines for Multiple Sclerosis

Growth in revenue from MS drugs has been driven largely by price increases over the last several years.

News on modifying diseases therapies. Michel CLANET CHU Toulouse France ECTRIMS

EMEA PUBLIC STATEMENT ON LEFLUNOMIDE (ARAVA) - SEVERE AND SERIOUS HEPATIC REACTIONS -

New England Pain Management Consultants At New England Baptist Hospital

Teriflunomide (Aubagio) 14mg once daily tablet

UPDATED INVESTOR PRESENTATION June 2015

Laquinimod Polman, C. et al. Neurology 2005;64:

Information about medicines for multiple sclerosis

SOUTH TAMPA MULTIPLE SCLEROSIS CENTER PATIENT/ CARE GIVER QUESTIONNAIRE

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market

MEDICAL ASSISTANCE BULLETIN

Eastern Health MS Service. Tysabri Therapy. Information for People with MS and their Families

Relapsing-remitting multiple sclerosis Ambulatory with or without aid

Preconception Clinical Care for Women Medical Conditions

Disease modifying drug therapy

Multiple sclerosis disease-modifying drugs second line treatments

Reintegration. Recovery. Medication-Assisted Treatment for Alcohol Dependence. Reintegration. Resilience

St. Luke s MS Center New Patient Questionnaire. Name: Date: Birth date: Right or Left handed? Who is your Primary Doctor?

IMPORTANT DRUG WARNING Regarding Mycophenolate-Containing Products

Drug Use Research & Management Program Phone Fax Generic Name: Brand Name (Manufacturer): PDL Class: Comparator Therapies: Dossier received:

fingolimod, 0.5mg, hard capsules (Gilenya ) SMC No. (992/14) Novartis Pharmaceuticals UK

Has the medication received FDA approval? Yes the FDA approved dimethyl fumarate on March 27, 2013.

Natalizumab (Tysabri)

The MS Disease- Modifying Medications

Medication Policy Manual. Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014

Version History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author

Liver Disease & Hepatitis Program Providers: Brian McMahon, MD, Steve Livingston, MD, Lisa Townshend, ANP. Primary Care Provider:

CNS DEMYLINATING DISORDERS

Study Support Materials Cover Sheet

TYSABRI Risk Management Plan. Carmen Bozic, MD Vice President Drug Safety and Risk Management Biogen Idec Inc

UW MEDICINE PATIENT EDUCATION. Xofigo Therapy. For metastatic prostate cancer. What is Xofigo? How does it work?

Interferons (Avonex, Betaferon, Rebif ) for relapsing remitting multiple sclerosis (RRMS)

Literature Scan: Oral Multiple Sclerosis Drugs

SECTION 2. Section 2 Multiple Sclerosis (MS) Drug Coverage

fingolimod (as hydrochloride), 0.5mg hard capsules (Gilenya ) SMC No. (763/12) Novartis Pharmaceuticals UK Ltd

MEDICATION GUIDE mitoxantrone (mito-xan-trone) for injection concentrate

FAQs about Warfarin (brand name Coumadin )

MEDICATION GUIDE ACTOPLUS MET (ak-tō-plus-met) (pioglitazone hydrochloride and metformin hydrochloride) tablets

See 17 for PATIENT COUNSELING INFORMATION. Revised: 3/2016 FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: ADRENAL CRISIS IN THE SETTING OF SHOCK OR

Oxford University Hospitals. NHS Trust. Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis. Information for patients

Form ### Transgender Hormone Therapy - Estrogen Informed Consent SAMPLE

A blood sample will be collected annually for up to 2 years for JCV antibody testing.

MEDICATION GUIDE COUMADIN (COU-ma-din) (warfarin sodium)

MEDICAL POLICY STATEMENT

What You Need to KnowWhen Taking Anticoagulation Medicine

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Multiple Sclerosis Agents

MEDICATION GUIDE JUXTAPID (JUKS-tuh-pid) (lomitapide) capsules

Biologic Treatments for Rheumatoid Arthritis

Understanding How Existing and Emerging MS Therapies Work

Uncertainty in Benefit and Risk: Tysabri (natalizumab)

A guide to the accelerated elimination procedure

Disease Modifying Therapies (DMTs) in Multiple Sclerosis

New Developments in the Treatment and Management of Multiple Sclerosis

Pharmacologic Therapies for Multiple Sclerosis: From injectable to oral agents

NHS BOURNEMOUTH AND POOLE AND NHS DORSET

Transcription:

ORAL MEDICATIONS FOR MS! Gilenya and Aubagio Champions against MS 4/20/13 Alexandra Goodyear, MD Stanford University

Oral Medications Since 2010, 3 new oral medications for MS: Gilenya 2010 Aubagio 2012 Tecfidera 2013 Opportunity to improve quality of life. But does new and/or oral = better for you?

Agenda Aubagio Mechanism of action, Metabolism Trial data Warnings, Adverse events Gilenya Mechanism of action, Metabolism Trial data Warnings, Adverse events Is changing medications ok? How do I know when to switch? How do I pick the right drug for me?

Aubagio 2nd oral drug for MS 2012 Once-daily pill 7 mg or 14 mg Active metabolite of Arava 1998 FDA-approved for rheumatoid arthritis Though new for MS, there is 14 yrs experience in RA

Aubagio Mechanism of Action Exact mechanism of action not fully understood. Blocks an enzyme necessary for active production of new T and B cells. Old T and B cells can still be recycled. Immunosuppressive?

Aubagio Metabolism Eliminated via excretion into bile and/or urine. Can speed excretion by taking charcoal or cholestyramine. If need to get off Aubagio, can clear in 11 days Without using charcoal or cholestyramine, Aubagio can remain in the body for up to 2 years.

Aubagio Phase III Trials TESMO: FDA approval based on this study TOWER TENERE

TESMO: Aubagio vs. placebo ARR Risk of 3 month sustained disability Risk of 6 month sustained disability 14mg Aubagio 31.2% reduction 29.8% reduction No difference from placebo 7mg Aubagio 31.5% reduction No difference from placebo No difference from placebo placebo ----- ----- -----

TOWER: Aubagio vs. placebo ARR Risk of 3 month sustained disability 14mg Aubagio 36.3% reduction 31.5% reduction 7mg Aubagio 22.3% reduction No difference from placebo placebo ----- -----

TENERE: Aubagio vs. Rebif Endpoints: Annualized relapse rate Occurrence of relapse Drug discontinuation No significant difference between 14mg Aubagio and Rebif for any of the endpoints. 7mg Aubagio performed worse than Rebif.

Take-Aways: Aubagio Dose: 7mg or 14mg? 14mg If your MS is not being well-controlled by a first-line MS drug: Aubagio is not a good option for you.

Aubagio Black Box Warnings Liver toxicity Interference with normal fetal development

Aubagio Warnings/Precautions Severe liver injury reported in Arava Screen liver blood tests in all patients Pregnancy excluded prior to start Patients counseled on serious fetal risk If elevated liver blood tests, or pregnant or want to become pregnant: Accelerated elimination procedure

Accelerated Elimination Procedure Cholestyramine 8 gms every 8 hrs x 11 days Oral activated charcoal powder 50 gms every 12 hours x 11 days At end of 11 days, 98% decrease in Aubagio blood concentration.

Aubagio Adverse events Abnormal liver blood tests Hair loss Diarrhea Flu Nausea Abnormal sensation/numbness/tingling

Drug Interactions ALWAYS tell your neurologist ALL the drugs you are taking. Aubagio may increase blood levels of: Some diabetes medications Oral contraceptives Warfarin (Coumadin): Aubagio decreases INR May decrease levels of cymbalta, tizanidine and others

Gilenya First oral drug for MS 2010 0.5 mg orally once daily First in class No other drugs like this on the market

Gilenya Mechanism of action Exact mechanism in MS unknown Sphingosine 1 phosphate (S1P) receptor blocker Some T cells require S1P receptor to leave lymph nodes When S1P receptor blocked, T cells remain in lymph nodes T cells not killed or destroyed. Memory T cells responsible for protection against repeat infections are not effected Immunosuppressive?

Gilenya metabolism Metabolized in liver Excreted in bowel and urine

Gilenya Phase III Trials FREEDOMS TRANSFORMS FREEDOMS II

FREEDOMS: Gilenya vs. Placebo 1.25 mg Gilenya 0.5 mg Gilenya placebo ARR Risk 3 month sustained disability Risk 6 month sustained disability Mean EDSS at 2 Years 60% reduction 32% reduction 30% reduction Decreased 0.03 54% reduction 30% reduction 30% reduction No change ----- ----- ----- Increased 0.13

TRANSFORMS: Gilenya vs. Avonex ARR Risk of 3 month sustained disability* Mean EDSS at 1 Year 1.25mg Gilenya 38% reduction No difference from Avonex Decreased 0.11 0.5mg Gilenya 52% reduction No difference from Avonex Decreased 0.08 Avonex ----- ----- Increased 0.01 *Trial only 12 months

FDA Safety Recommendations for Gilenya Updated April 2012: After a death following 1st dose. Included review of trial and post-marketing data. Gilenya now contraindicated in patients: With certain pre-existing or recent (within last 6 months) heart conditions or stroke Who are taking certain antiarrhythmic (heart) medications.

FDA recommendations on Gilenya 1st Dose Monitoring ALL patients starting Gilenya Monitored for signs of a slow heart rate for at least 6 hours after 1st dose Hourly pulse and blood pressure measurement EKG before dosing and at the end of observation In patients who are at higher risk for or who may not tolerate slow heart rate: Time of monitoring extended past 6 hours Including continuous monitoring overnight

Who are high risk patients? Develop severe slow heart rate after 1st dose With certain pre-existing conditions in whom slow heart rate may be poorly tolerated With certain heart rhythm abnormalities Receiving therapy with other drugs that: Slow the heart rate Alter the hearts electrical conduction

Gilenya Warnings/Precautions Decrease in heart rate and/or electrical heart conduction ĺ 1st dose monitoring. Infections: Possible increased risk of infections. Macular edema: 0.4% of patients. Can occur with or without visual symptoms. Ophthalmologic evaluation before starting and 3-4 months later. Patients with diabetes mellitus or a history of uveitis at higher risk. Decrease in pulmonary function Liver effects: follow with blood tests. Pregnancy: wait 2 months after stopping before trying to conceive.

Gilenya Adverse events: Headache Flu Diarrhea Back pain Liver test elevations Cough

Drug Interactions ALWAYS tell your neurologist ALL the drugs you are taking. Ketoconazole increases Gilenya levels. Gilenya contraindicated in patients taking certain heart medications antiarrhythmic

Is changing MS medications ok? Yes BUT: Not every available drug is suited for every individual. Changes with your neurologist s advice and OK.

How do I know when to switch? Disease poorly controlled: Multiple relapses on current medication Multiple new enhancing lesions on MRI or Current medication intolerable: Side effects of current medication intolerable You are skipping your medication with regularity

Which MS medication is for me? We don t know (yet). It depends Are you having relapses despite treatment? Is your MRI worsening despite treatment? Tysabri Gilenya Tecfidera Are you stable but tired of injections? Gilenya Tecfidera Aubagio (If done having kids)

Thank You Questions?